Status:
COMPLETED
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
Lead Sponsor:
Pfizer
Conditions:
Pneumococcal Conjugate Vaccine
Eligibility:
All Genders
6-17 years
Phase:
PHASE3
Brief Summary
This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent p...
Eligibility Criteria
Inclusion
- Male or female subject between the ages of \>=6 to \<18 years.
- Diagnosis of SCD
- 23vPS vaccination at least 6 months prior to enrollment.
Exclusion
- Previous vaccination with pneumococcal conjugate vaccine.
- Previous reaction to any vaccine or vaccine-related component or contraindication to vaccination with pneumococcal conjugate vaccine.
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT00918580
Start Date
November 1 2009
End Date
March 1 2013
Last Update
April 21 2014
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
2
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202-3830
3
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
4
Pfizer Investigational Site
The Bronx, New York, United States, 10467